MarketCapExport financials
Eagle Pharmaceuticals (EGRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Eagle Pharmaceuticals Financial Ratios 2022-2011 | EGRX
Brief overview of Eagle Pharmaceuticals's valuation and returns
Ratios are assessed across five available annual reports in the 2017–2022 interval.
Key multiples at the end of the period are P/E 9.54x (median 19.56x), EV/EBITDA 5.6x (median 17.54x), P/S 1.07x (median 3.35x). The current ratio basket stands about 57.2% below the five-year comparison base. Earnings and risk trends should explain the discount.
Current earnings relative to valuation equal about 10.5% on the 1/P/E measure. This is a valuation reference, not an expected payout.
End-period return metrics are ROE 15.3%, ROA 8.8%, ROCE 34.7%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
The time from paying for inputs to receiving cash rose from 66.4 days to 138.7 days. Cash turnover slowed.
What the ratios show
Eagle Pharmaceuticals's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.
Annual Financial Ratios Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.5 | -69.5 | 52.5 | 51.7 | 19.6 | 17.4 | 13.2 | 426.5 | -49.5 | - | - | - | |
P/S |
1.1 | 3.5 | 3.4 | 3.8 | 2.9 | 3.8 | 5.7 | 16.6 | 14.3 | - | - | - |
EPS |
2.8 | -0.7 | 0.9 | 1.0 | 2.2 | 3.4 | 5.2 | 0.2 | -0.4 | -1.4 | -14.1 | - |
EV (Enterprise Value) |
457 M | 579 M | 593 M | 706 M | 623 M | 879 M | 1.09 B | 1.05 B | 258 M | 5.59 M | 16.5 M | - |
EBITDA per Share |
6.31 | 0.27 | 2.51 | 1.66 | 2.56 | 4.96 | 3.48 | 0.18 | -0.47 | -0.96 | -11.8 | - |
EV/EBITDA |
5.6 | 163.9 | 17.5 | 31.0 | 16.5 | 11.7 | 20.1 | 393.6 | -39.4 | -1.9 | -0.8 | - |
PEG |
0.02 | 4.4 | 0.14 | 0.16 | 0.06 | 0.05 | 0.0 | 3.93 | 0.03 | - | - | - |
P/B |
1.5 | 3.4 | 3.4 | 4.1 | 3.9 | 5.0 | 7.1 | 12.1 | 9.1 | - | - | - |
P/CF |
6.7 | 21.2 | 12.7 | 13.2 | 11.9 | 15.3 | 20.2 | -112.8 | -34.6 | - | - | - |
ROE % |
15.26 | -4.89 | 6.45 | 7.99 | 19.84 | 29.00 | 53.86 | 2.85 | -19.73 | 3.70 | 20.75 | - |
ROA % |
8.78 | -3.40 | 4.74 | 5.62 | 13.37 | 19.23 | 38.01 | 2.06 | -10.99 | -17.98 | -205.37 | - |
ROCE % |
34.66 | 1.57 | 17.72 | 10.11 | 18.41 | 33.22 | 30.78 | 2.83 | -23.52 | 3.55 | 21.37 | - |
Current Ratio |
2.4 | 3.3 | 3.8 | 3.4 | 3.1 | 3.0 | 3.4 | 3.6 | 2.5 | 1.1 | 0.4 | - |
DSO |
65.5 | 98.2 | 96.3 | 106.7 | 102.9 | 74.0 | 65.9 | 105.3 | 163.2 | 68.4 | - | - |
DIO |
148.9 | 173.6 | 79.4 | 56.7 | 57.8 | 42.5 | 90.7 | 189.9 | 127.2 | - | - | - |
DPO |
75.6 | 131.4 | 63.6 | 58.6 | 94.3 | 144.5 | 94.7 | 85.8 | 480.6 | 81.5 | - | - |
Operating Cycle |
214.3 | 271.7 | 175.7 | 163.3 | 160.7 | 116.6 | 156.6 | 295.3 | 290.4 | 68.4 | - | - |
Cash Conversion Cycle |
138.7 | 140.3 | 112.1 | 104.7 | 66.4 | -28.0 | 61.9 | 209.4 | -190.2 | -13.1 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.39 | 0.44 | - | -0.54 | -0.74 | 3.47 | - | -0.43 | 0.28 | -0.03 | - | 0.52 | -0.02 | -0.21 | 0.08 | -0.17 | 0.49 | 0.64 | 0.86 | 0.94 | 0.18 | 0.18 | 0.61 | 1.03 | 0.3 | 1.5 | 3.75 | 0.77 | 0.84 | -0.06 | 0.08 | -0.65 | -0.53 | 1.38 | -0.39 | -0.21 | -0.36 | -0.36 | -1.44 | -3.06 | -0.11 | -1.84 | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.79 | 0.91 | - | 0.73 | 0.19 | 4.72 | - | -0.76 | 0.84 | -0.27 | - | 1.15 | 0.29 | 0.31 | - | -0.07 | 0.74 | 0.91 | - | 1.29 | 0.06 | 0.18 | 0.7 | 1.7 | 0.42 | 2.16 | - | 0.82 | 0.89 | -0.05 | 0.08 | -0.66 | -0.53 | 1.41 | -0.47 | -0.21 | -0.4 | -0.4 | -1 | -1.93 | 0.44 | -1.41 | - | - | - | - | - | - | - | - |
ROE % |
-2.63 | 15.72 | 13.35 | 10.32 | 15.25 | 19.00 | -1.40 | 2.68 | 5.58 | 2.15 | 2.37 | 1.01 | 0.82 | 6.08 | 7.66 | 14.89 | 17.68 | 15.25 | 10.13 | 19.15 | 14.64 | 26.95 | 25.48 | 36.81 | 39.94 | 36.24 | 22.50 | 23.85 | 0.92 | -19.70 | 0.41 | -20.66 | -16.06 | -13.59 | -42.35 | -15.20 | -9.05 | -9.62 | - | 7.43 | -0.86 | - | - | - | - | - | - | - | - | - |
ROA % |
-1.66 | 10.83 | 9.44 | 7.25 | 10.46 | 12.77 | -0.99 | 1.86 | 3.95 | 1.79 | 1.95 | 1.02 | 0.75 | 4.31 | 5.10 | 10.32 | 12.22 | 10.70 | 7.24 | 13.03 | 9.85 | 19.07 | 18.02 | 26.17 | 29.16 | 26.42 | 16.22 | 17.20 | 0.73 | -14.79 | 1.06 | -10.91 | -7.63 | -5.07 | -25.59 | -50.68 | -41.47 | -5.36 | - | -36.08 | 4.17 | - | - | - | - | - | - | - | - | - |
ROCE % |
13.94 | 37.56 | 32.71 | 27.22 | 28.69 | 25.79 | -1.91 | 7.01 | 14.52 | 11.18 | 13.16 | 14.77 | 4.44 | 7.78 | 12.50 | 20.66 | 31.56 | 26.30 | 20.66 | 16.70 | 21.81 | 25.28 | 43.58 | 56.46 | 53.53 | 62.63 | 42.06 | 24.68 | 1.16 | -20.15 | 0.35 | -24.49 | -19.75 | -19.18 | -51.61 | -21.35 | -15.67 | -12.91 | - | 6.74 | -1.43 | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.6 | 2.4 | 2.4 | 2.5 | 2.7 | 3.1 | 3.3 | 3.6 | 3.8 | 3.8 | 3.8 | 3.3 | 3.5 | 2.0 | 3.4 | 3.4 | 3.5 | 3.4 | 3.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
162.4 | 128.9 | - | 126.6 | 133.4 | 67.7 | - | 112.2 | 92.5 | 106.2 | - | 90.5 | 110.2 | 101.6 | 87.8 | 116.6 | 100.0 | 119.5 | 118.0 | 131.4 | 94.5 | 104.9 | 122.3 | 90.4 | 125.6 | 75.4 | 50.2 | 119.5 | 87.6 | 81.4 | 96.6 | 200.4 | 178.6 | 28.2 | 152.1 | 235.9 | 155.8 | 109.0 | 42.6 | 51.7 | 46.1 | - | - | - | - | - | - | - | - | - |
DIO |
234.4 | 242.5 | - | 265.8 | 177.9 | 84.7 | - | 146.4 | 87.5 | 80.7 | - | 75.7 | 72.2 | 143.6 | - | 70.8 | 54.9 | 88.7 | - | 72.6 | 40.8 | 71.1 | - | 80.2 | 33.8 | - | - | 59.0 | 56.2 | 71.3 | - | 117.6 | 59.2 | 25.0 | 40.2 | 46.1 | 33.7 | 16.9 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
89.2 | 95.2 | - | 72.5 | 74.3 | 56.1 | - | 198.4 | 136.7 | 101.8 | - | 140.0 | 103.8 | 145.7 | - | 107.2 | 85.6 | 127.5 | - | 136.6 | 89.5 | 134.8 | - | 199.5 | 159.6 | - | - | 107.4 | 86.4 | 44.3 | - | 230.1 | 139.2 | 68.5 | 154.2 | 146.0 | 80.9 | 47.5 | 20.4 | 24.4 | 18.6 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
396.8 | 371.4 | - | 392.4 | 311.3 | 152.4 | - | 258.6 | 179.9 | 186.9 | - | 177.1 | 181.7 | 238.0 | 90.8 | 155.8 | 110.2 | 175.9 | 108.2 | 206.1 | 156.2 | 202.5 | 105.0 | 174.9 | 150.4 | 57.0 | 47.5 | 125.7 | 115.9 | 161.2 | 131.8 | 783.6 | 809.3 | 172.9 | 258.4 | 440.2 | 261.2 | 125.8 | 42.6 | 51.7 | 46.1 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
307.6 | 276.2 | - | 319.8 | 237.0 | 96.3 | - | 60.3 | 43.2 | 85.2 | - | 111.5 | 126.3 | 125.7 | 90.8 | 114.8 | 82.8 | 102.5 | 108.2 | 101.1 | 91.8 | 64.2 | 105.0 | -52.1 | 27.7 | 57.0 | 47.5 | -3.1 | -1.2 | 103.1 | 131.8 | 689.8 | 704.2 | 116.5 | 79.2 | 293.3 | 55.9 | 78.3 | 22.2 | 27.3 | 27.5 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Eagle Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
Canada
China
Irlanda
Schweden
